Page 16 - Program Phase News Today

Chemotherapy (CEP).  Noxopharm CEO Dr Graham Kelly said: “Our 4-pillars Veyonda strategy is behind an ambitious goal of bringing Veyonda to market as a general-purpose drug that boosts the effectiveness of common cancer therapies.  “One of those pillars, the CEP program, is looking at using Veyonda to make standard chemotherapy more effective in general, but to do it in a way that also makes it a lot safer.  “If we can achieve that, more patients should benefit with better responses an...

The Need for Comprehensive Diagnostics Remains as Cases Spike Once More FinancialBuzz.com News Commentary Share this article Share this article NEW YORK, April 20, 2021 /PRNewswire/ -- The Director of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and many other experts have warned that rapid reopening and lifting of pandemic restrictions in many states, as well as the proliferation of more contagious variants, will likely result in ongoing and increased spr...

Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline plc (NYSE: GSK) have provided an update on the VIR-7831 ...

DGAP-News: CureVac / Key word(s): Study CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma 04.02.2021 / 13:10 CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma - - Trial expansion focuses on advanced melanoma, an indication of high medical need TÜBINGEN, Germany / BOSTON, USA - February 4, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic ac...

Share this article Share this article INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as...

(2) TORONTO, ON / ACCESSWIRE / January 12, 2021 / Gratomic Inc. ("Gratomic" or the "Company") (TSXV:GRAT)(FRANKFURT:CB82)(WKN:A143MR)(OTCQB:CBULF) wishes to announce that it has upgraded its pre purchase agreement with technology company, TODAQ Star Program Phase 1 Corp.(" TODAQ"), a subsidiary of TODAQ Holdings Inc., pursuant to the terms of a new agreement dated January 7, 2020 between the Company and TODAQ (the " Supply Agreement") to provide battery grade graphite SG16 for the EV Battery M...

COMMERCIAL POINT — Pickaway County Public Health has received the first 100 doses of the Moderna COVID-19 vaccine and the doses have been administered to EMS personnel starting this week. Scioto Township Fire Chief Neil Cline, 48, was the first person to receive the Moderna Vaccine administered in Pickaway County by Pickaway County Public Health. Cline said he volunteered to be the first one to set an example for his fellow first responders and the community and that he believes in the sci...

News Category Global Banking & Finance Reviews Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 – Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec....

ValOre Drills Near-Surface PGE Mineralization at Trapia 2 Target, Pedra Branca: VANCOUVER, British Columbia, Dec. 17, 2020 — ValOre Metals Corp. (“ValOre”; TSX ‐ V: VO; OTC: KVLQF; Frankfurt: KEQ0, “the Company”) today announced assay results for eight Trapia 2 core drill holes at ValOre’s 100%-owned Pedra Branca Platinum Group Element (“PGE”) Project in northeastern Brazil. The target ultramafic (“UM”) Trapia 2 intrusion was intercepted in all eight core holes drilled, e...

ValOre Drills Near-Surface PGE Mineralization at Trapia 2 Target, Pedra Branca: 45.62 metres grading 0.54 g/t 2PGE+Au from 9.10m and 52.15 metres grading 0.49 g/t 2PGE+Au from 4.85 metres Vancouver, B.C. ValOre Metals Corp. ("ValOre"; TSX‐V: VO; OTC: KVLQF; Frankfurt: KEQ0, "the Company") today announced assay results for eight Trapia 2 core drill holes at ValOres 100%-owned Pedra Branca Platinum Group Element ("PGE") Project in northeastern Brazil. The target ultramafic...